Correction: Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group.

Abstract

The authors have noticed that the final paragraph of the Results section contains errors in the number of patients involved. The correct number of patients is included in the text below. These errors do not affect the Figure referenced.In osteosarcoma, we focused on 8q gain as a specific biological feature of interest. Among the 41 patients with detectable ctDNA in the osteosarcoma cohort, 8q gain was detected in 73.2% (30/41). The 3-year EFS for patients with 8q gain (n = 30) in ctDNA was 60.0% (95% CI 40.5-75.0) compared to 80.8 (95% CI 42.4-94.9) in patients without 8q gain (n = 11) in ctDNA (p = 0.18; Fig. 3).

• Authors: David S Shulman, Kelly Klega, Alma Imamovic-Tuco, Andrea Clapp, Anwesha Nag, Aaron R Thorner, Eliezer Van Allen, Gavin Ha, Stephen L Lessnick, Richard Gorlick, Katherine A Janeway, Patrick J Leavey, Leo Mascarenhas, Wendy B London, Kieuhoa T Vo, Kimberly Stegmaier, David Hall, Mark D Krailo, Donald A Barkauskas, Steven G DuBois, Brian D Crompton
• Journal: British journal of cancer (Br J Cancer) Vol. 120 Issue 8 Pg. 869 (Apr 2019) ISSN: 1532-1827 [Electronic] England
• PMID: 30880335 (Publication Type: Published Erratum)